The drug name of Ambrovir, Irbesartan, is a potent orally active selective angiotensin-II receptor antagonist. It blocks all the effects of angiotensin-II mediated by the AT1 receptor. Its selective antagonism of angiotensin-II receptors leads to an increase in plasma renin-angiotensin levels and a decrease in plasma aldosterone levels. In patients without electrolyte disturbances, serum potassium is not significantly affected when the recommended dose of irbesartan is administered alone. It is used clinically in the treatment of primary hypertension, combined with hypertension in the treatment of type 2 diabetic nephropathy.